Refine USA, LLC – Trademark Portfolio
Entity Type: 16
Refine USA, LLC owns a portfolio of 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as BRISTLE, AURA 365, REJUVAPEN, ONTOGENY-C, and TRU VERTICAL. Of these, 6 are registered. The portfolio spans 5 Nice Classification classes, led by Class 10 (Medical Apparatus) and Class 44 (Medical Services). Headquartered in Jacksonville Beach, FL.
340 3rd Avenue South Suite C
Jacksonville Beach, FL 32250
Showing of trademarks Trademarks
Trademark Classifications
Refine USA, LLC's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Refine USA, LLC have?
Refine USA, LLC has 16 U.S. trademarks filed with the USPTO. Of these, 6 registered, 7 abandoned, 3 cancelled.
What trademark classes does Refine USA, LLC file in?
Refine USA, LLC files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 7 (Machinery). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Refine USA, LLC's most well-known trademarks?
Refine USA, LLC's registered trademark portfolio includes well-known marks such as BRISTLE, AURA 365, REJUVAPEN, ONTOGENY-C, and TRU VERTICAL. These are among 6 currently registered trademarks in the portfolio.
What is Refine USA, LLC's trademark registration success rate?
Refine USA, LLC has a 38% trademark registration rate, with 6 out of 16 resolved applications resulting in successful registration. Currently, 0 applications are pending review.